Aaron D. Solomon
Plus aucun poste en cours
Profil
Aaron D.
Solomon worked as Senior Director of Business Development at Incyte Corp.
He then worked as Vice President of Worldwide Industrial Sales at Affymetrix, Inc. for a year.
After that, he worked as Vice President of Business Development at ParAllele BioScience, Inc. for a year.
He then worked as Vice President of Business Development at Tethys Bioscience, Inc. for a year.
Later, he worked as Vice President of Worldwide Sales at Complete Genomics, Inc. for three years.
Finally, he worked as Senior Vice President of Commercial at Station X, Inc. Mr. Solomon completed his undergraduate degree from the University of California, Irvine.
Anciens postes connus de Aaron D. Solomon
| Sociétés | Poste | Fin |
|---|---|---|
| COMPLETE GENOMICS, INC. | Corporate Officer/Principal | 16/11/2010 |
Tethys Bioscience, Inc.
 Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | Corporate Officer/Principal | 01/03/2009 |
| AFFYMETRIX, INC. | Sales & Marketing | 01/04/2008 |
ParAllele BioScience, Inc.
 ParAllele BioScience, Inc. Miscellaneous Commercial ServicesCommercial Services ParAllele BioScience, Inc. provides genetic discovery solutions to the life science research, pharmaceutical and diagnostic sectors. The company's products and services utilize a multiplexed approach that leverages novel biochemical processes rather than complex instrumentation to discover and analyze minute variations in the human genome. The company was founded in October, 2001 and is located in San Francisco, CA. | Corporate Officer/Principal | 01/10/2005 |
Station X, Inc.
 Station X, Inc. Packaged SoftwareTechnology Services Station X, Inc. develops software products for scientists and clinicians. It provides products to scientists who work with large-scale human genome information in either a research or clinical setting, enabling them to extract maximal biological meaning from complex genomic data. The company was founded by Richard D. Goold, Tod M. Klingler and Andrew R. MacBride in August 2010 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | - |
Formation de Aaron D. Solomon
| University of California, Irvine | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| Entreprise privées | 5 |
|---|---|
Complete Genomics, Inc.
 Complete Genomics, Inc. BiotechnologyHealth Technology Complete Genomics, Inc. develops and markets DNA sequencing technology. It provides complete genomics analysis platform, which combines its proprietary human genome sequencing technology with the company's advanced informatics and data management software. The firm offers innovative, end-to-end, outsourced service model to the customers with data. The company was founded by Clifford A. Reid, Radoje T. Drmanac, David Smith and Robert John Curson in 2006 and is headquartered in San Jose, CA. | Health Technology |
Affymetrix, Inc.
 Affymetrix, Inc. Medical SpecialtiesHealth Technology Affymetrix, Inc. develops, manufactures and sells products and services for genetic analysis. The company was founded by Stephen P. A. Fodor in 1992 and is headquartered in Santa Clara, CA. | Health Technology |
ParAllele BioScience, Inc.
ParAllele BioScience, Inc. Miscellaneous Commercial ServicesCommercial Services ParAllele BioScience, Inc. provides genetic discovery solutions to the life science research, pharmaceutical and diagnostic sectors. The company's products and services utilize a multiplexed approach that leverages novel biochemical processes rather than complex instrumentation to discover and analyze minute variations in the human genome. The company was founded in October, 2001 and is located in San Francisco, CA. | Commercial Services |
Tethys Bioscience, Inc.
Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | Health Technology |
Station X, Inc.
Station X, Inc. Packaged SoftwareTechnology Services Station X, Inc. develops software products for scientists and clinicians. It provides products to scientists who work with large-scale human genome information in either a research or clinical setting, enabling them to extract maximal biological meaning from complex genomic data. The company was founded by Richard D. Goold, Tod M. Klingler and Andrew R. MacBride in August 2010 and is headquartered in San Francisco, CA. | Technology Services |